Fractionated 90 Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for ... Monthly Prescribing Reference Patients with >20% bone marrow (BM) involvement received fractionated RIT only if a repeat BM biopsy demonstrated a reduction to ≤20% involvement following four weekly infusions of rituximab 375mg/m 2 . The primary endpoint was the end of treatment ... |
